Insulin glargine 300 U/mL safety data in pregnancy

被引：0
|
作者：
Westerbacka, Jukka [1 ]
Duverne, Marielle [1 ]
Grulovic, Natasa [1 ]
Thummisetti, Sreenivas [2 ]
Doder, Zoran [3 ]
机构：
[1] Sanofi, 46 Ave Grande, F-75017 Paris, France
[2] Sanofi, Hyderabad, India
[3] Sanofi, Bridgewater, MA USA
来源：
DIABETES OBESITY & METABOLISM | 2025年 / 27卷 / 05期
关键词：
gestational diabetes; glycaemic control; hypoglycaemia; insulin glargine; pregnancy; GLYCEMIC CONTROL; PERINATAL OUTCOMES; RANDOMIZED-TRIAL; ASPART; WOMEN; PROVIDES; DEGLUDEC; DETEMIR;
D O I：
10.1111/dom.16295
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2322 / 2325
页数：4
相关论文
共 50 条
  • [21] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [22] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [23] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Boris Kovatchev
    Zhaoling Meng
    Anna M. G. Cali
    Riccardo Perfetti
    Marc D. Breton
    Diabetes Therapy, 2020, 11 : 1293 - 1302
  • [24] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [25] Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naive people with type 2 diabetes: The EDITION AP randomized controlled trial
    Ji, Linong
    Kang, Eun Seok
    Dong, XiaoLin
    Li, Ling
    Yuan, GuoYue
    Shang, Shuhua
    Niemoeller, Elisabeth
    DIABETES OBESITY & METABOLISM, 2020, 22 (04): : 612 - 621
  • [26] Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study
    Chen, Liming
    Wen, Binhong
    Liu, Haixia
    Wu, Hongmei
    Duan, Binhong
    Shu, Hongyan
    Zhang, Qiu
    Wu, Xiaohong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4571 - 4582
  • [27] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [28] Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Gourdy, Pierre
    Bahloul, Amar
    Boultif, Zahra
    Gouet, Didier
    Guerci, Bruno
    DIABETES THERAPY, 2020, 11 (01) : 147 - 159
  • [29] Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Pierre Gourdy
    Amar Bahloul
    Zahra Boultif
    Didier Gouet
    Bruno Guerci
    Diabetes Therapy, 2020, 11 : 147 - 159
  • [30] Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
    Nakanishi, Shuhei
    Iwamoto, Masahiro
    Kamei, Shinji
    Hirukawa, Hidenori
    Shimoda, Masashi
    Tatsumi, Fuminori
    Kohara, Kenji
    Obata, Atsushi
    Kimura, Tomohiko
    Kinoshita, Tomoe
    Irie, Shintaro
    Sanada, Junpei
    Fushimi, Yoshiro
    Nishioka, Momoyo
    Mizoguchi, Akiko
    Kameyama, Miyuki
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    INTERNAL MEDICINE, 2018, 57 (10) : 1381 - 1389
12345